Note: Neurophage Pharmaceuticals's revenues are gauged from an analysis of company filings.
Neurophage Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
November 16, 2018
Complete list of funding rounds and total amounts in the Company Report
Neurophage Pharmaceuticals's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Neurophage Pharmaceuticals Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that Neurophage Pharmaceuticals is developing and marketing.
Neurophage Pharmaceuticals doesn't have any recent trademark applications, indicating Neurophage Pharmaceuticals is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
PROCLARA BIOSCIENCES Pharmaceutical preparations for use in the prevention and treatment of central nervous system diseases and disorders; pharmaceutical preparations for use in the prevention and treatment of diseases and disorders caused by misfolded protein deposits; pharmaceutical preparations for use in the prevention and treatment of Alzheimer's disease
NEUROPHAGE Pharmaceutical compositions for use in the prevention and treatment of diseases and disorders characterized by protein aggregation
Determine whether Neurophage Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Neurophage Pharmaceuticals is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Neurophage Pharmaceuticals's Largest Competitors
A competitive analysis shows these companies are in the same general field as Neurophage Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Neurophage Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Neurophage Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.